The Developmental Projects Program will sponsor efforts to complement or enhance the variety and depth of sarcoma translational research and will seek to ensure continual renewal of high-quality scientific endeavors in the SARC Sarcoma SPORE. The Program will support short-range studies to establish the results needed to facilitate well-validated, hypothesis-driven translational projects. Although the Developmental Projects Program will fund established investigators, an important goal is to identify and stimulate interest in sarcoma research among groups whose current focus may be different but sufficienfiy related. The Program may also fund projects that contribute to the infrastructure needed to achieve translational goals, such as creafion of suitable fissue resources or development of a new assay to monitor tumor behavior. The Developmental Projects Program is led by Francis Hornicek, an orthopaedic oncologist and co-Director, MGH/DF/HCC Sarcoma Group, whose laboratory evaluates mechanisms of sarcoma drug resistance, and Paul Meltzer, Chief of the Genefics Branch at the Center for Cancer Research, NCI, a pediatric oncologist who examines genomic mechanisms in sarcoma pathogenesis. In addifion, a highly qualified committee of experienced clinician-scientists will participate actively in the selecfion and ongoing review of pilot projects. The committee includes members with expertise in key aspects of sarcoma science and therapeufics, including biology and genetics (Drs. Pollock, Look and J. Fletcher);animal models (Drs. Khanna and Look), developmental therapeufics (Drs. Demetri and Pienta), clinical trials (Drs. Pollock, Pienta, and Demetri), correlafive science (Drs. Khanna and J. Fletcher), sarcoma pathology and molecular diagnosfics(Drs. C. Fletcher, Hamilton, and J. Fletcher), sarcoma genomics (Dr. Meltzer and J. Fletcher), sarcoma drug resistance (Dr. Homicek), and comparative oncology (Dr. Khanna). This committee includes representafives from Brigham and Women's Hospital, Dana-Farber Cancer Insfitute, Children's Hospital - Boston, Massachusetts General Hospital Cancer Center, MD Anderson Cancer Center, University of Michigan, and the National Cancer Insfitute. Nurturing innovations in translafional research is a labor-intensive activity, which must occur in cross-disciplinary fashion, and therefore the Developmental Projects Committee includes representation of pediatric oncology, medical oncology, surgical oncology, orthopaedic oncology, veterinary medicine (comparative oncology), pathology, and basic science. The Developmental Projects Program will provide the depth and flexibility required to maintain innovation in SARC Sarcoma SPORE.

Public Health Relevance

The Developmental Research Program will maximize the SPORE impact by enabling novel translafional sarcoma projects to develop and mature. These developmental projects will add new concepts to the SPORE, and will ensure that the SPORE translatlonal/clinical progress remains vigorous and with a varied portfolio of experimental work to draw upon, for main projects.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ann Arbor
United States
Zip Code
Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92
Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23
Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13
Mariño-Enríquez, Adrián; Bovée, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73
Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358
Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4
Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43
Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28
Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415
De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28

Showing the most recent 10 out of 86 publications